Impact Biomedical Inc. (IBO) intrinsic value & 10-year financials
Impact Biomedical Inc. (IBO) has a Graham intrinsic value of $6.27 per share. At $2.68 on Oct 17, 2026, the stock trades 57% below that value. Over the last 5 fiscal years revenue shrank 13.8% a year to $32.0K, with an average return on invested capital of -42.4%.
- Graham intrinsic value
- $6.27
- Share price (Oct 17, 2026)
- $2.68
- Price vs Graham value
- 57% below
- Market cap
- $83.5M
- Revenue (FY2025)
- $32.0K
- Revenue growth (5-yr CAGR)
- -13.8%
- ROIC (10-yr avg)
- -42.4%
- Free cash flow (FY2025)
- —
IBO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $32.0K | -$11.8M | -$0.38 | — | -13381.2% | -31.6% |
| FY2024 | — | -$24.7M | -$2.30 | — | — | -118.7% |
| FY2023 | — | -$4.4M | -$0.07 | — | — | -11.5% |
| FY2022 | $50.0K | -$7.3M | -$0.10 | — | -6808.0% | -7.9% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
IMPACT BIOMEDICAL INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
IMPACT BIOMEDICAL INC. has historically struggled to out-earn its cost of capital, averaging just -42.4% ROIC.
IMPACT BIOMEDICAL INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, IMPACT BIOMEDICAL INC. is modeled at -13.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $6.27 per share.